Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals

[1]  M. Salvatore,et al.  In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  G. Morelli,et al.  A Cyclic CCK8 Analogue Selective for the Cholecystokinin Type A Receptor: Design, Synthesis, NMR Structure and Binding Measurements , 2003, Chembiochem : a European journal of chemical biology.

[3]  J. Reubi.  Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.

[4]  E. Blomquist,et al.  Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran. , 2003, Nuclear medicine and biology.

[5]  T. Visser,et al.  Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  L. Gianni.  The Future of Targeted Therapy: Combining Novel Agents , 2002, Oncology.

[7]  Krzysztof Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Science.

[8]  G. Hortobagyi.  The Status of Breast Cancer Management: Challenges and Opportunities , 2002, Breast Cancer Research and Treatment.

[9]  S. Mather,et al.  The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[10]  R. Dillman.  Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Piserchio,et al.  Structural insight into the role of the second intracellular loop of the bradykinin 2 receptor in signaling and internalization. , 2002, Biopolymers.

[12]  D. Mierke,et al.  Peptide hormone binding to G‐protein‐coupled receptors: Structural characterization via NMR techniques , 2001, Medicinal research reviews.

[13]  G. Morelli,et al.  Synthesis and solution characterization of a porphyrin‐CCK8 conjugate , 2001, Journal of peptide science : an official publication of the European Peptide Society.

[14]  M. Béhé,et al.  Imaging tumors with peptide-based radioligands. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[15]  D. Mierke,et al.  Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin-2 receptor. , 2001, Biochemistry.

[16]  H. Li,et al.  Photoaffinity labeling of mutant neurokinin-1 receptors reveals additional structural features of the substance P/NK-1 receptor complex. , 2001, Biochemistry.

[17]  E P Krenning,et al.  Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  D. Neri,et al.  The use of phage display for the development of tumour targeting agents. , 2000, Advanced drug delivery reviews.

[19]  P. Carbone,et al.  Advances in the systemic treatment of cancers in the elderly. , 2000, Critical reviews in oncology/hematology.

[20]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[21]  G. Novelli,et al.  Transfer and expression of foreign genes in mammalian cells. , 2000, BioTechniques.

[22]  M. Pellegrini,et al.  Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy. , 1999, Biochemistry.

[23]  R. Jensen,et al.  Somatostatin receptor scintigraphy in gastrinomas. , 1999, Italian journal of gastroenterology and hepatology.

[24]  R. Pasqualini.  Vascular targeting with phage peptide libraries. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[25]  J. Bockaert,et al.  Molecular tinkering of G protein‐coupled receptors: an evolutionary success , 1999, The EMBO journal.

[26]  S. Wank.  I. CCK receptors: an exemplary family. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[27]  M. Béhé,et al.  Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin , 1998, European Journal of Nuclear Medicine.

[28]  H. Wagner,et al.  High-affinity no-carrier-added 99mTc-labeled chemotactic peptides for studies of inflammation in vivo. , 1998, Bioconjugate chemistry.

[29]  Heidi E. Hamm,et al.  The Many Faces of G Protein Signaling* , 1998, The Journal of Biological Chemistry.

[30]  D. Brough,et al.  Adenoviral vectors for gene transfer. , 1997, Current opinion in biotechnology.

[31]  T. Lybrand,et al.  Direct Identification of a Distinct Site of Interaction between the Carboxyl-terminal Residue of Cholecystokinin and the Type A Cholecystokinin Receptor Using Photoaffinity Labeling* , 1997, The Journal of Biological Chemistry.

[32]  T. Bártfai,et al.  Modes of Peptide Binding in G Protein-Coupled Receptors , 1997, Neurochemical Research.

[33]  B. Moyer,et al.  Pharmacokinetic considerations in the development of peptide-based imaging agents. , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[34]  T. Visser,et al.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy , 1997, European Journal of Nuclear Medicine.

[35]  H. Bourne,et al.  How receptors talk to trimeric G proteins. , 1997, Current opinion in cell biology.

[36]  B. Maigret,et al.  Identification of Two Amino Acids of the Human Cholecystokinin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin* , 1997, The Journal of Biological Chemistry.

[37]  T. Visser,et al.  Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  D. Venzon,et al.  Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study , 1996, Annals of Internal Medicine.

[39]  M. Welch,et al.  In vitro and in vivo evaluation of copper-64-octreotide conjugates. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  W. Scheithauer,et al.  Vasoactive intestinal peptide receptor scintigraphy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[42]  J. Viney.  Transgenic and gene knockout mice in cancer research , 1995, Cancer and Metastasis Reviews.

[43]  W. Scheithauer,et al.  Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. , 1994, The New England journal of medicine.

[44]  M. Gerretsen,et al.  Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  J. Baldwin.  The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[46]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[47]  S. Houle,et al.  In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[48]  M. Abrams,et al.  Preparation of hydrazino-modified proteins and their use for the synthesis of 99mTc-protein conjugates. , 1991, Bioconjugate chemistry.

[49]  G. Denardo,et al.  Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  K. Berkner.  Development of adenovirus vectors for the expression of heterologous genes. , 1988, BioTechniques.

[51]  S. Leahy.  Eight ‘Musts’ for Biotechnology , 1988, Bio/Technology.

[52]  H. Kirchgessner,et al.  Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate , 1986, European Journal of Nuclear Medicine.

[53]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[54]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[55]  H. Berendsen,et al.  Molecular dynamics: perspective for complex systems. , 1982, Biochemical Society transactions.

[56]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[57]  M. Karplus,et al.  Dynamics of folded proteins , 1977, Nature.

[58]  S. Watson,et al.  Targeting of Cholecystokinin B/gastrin receptor in cancer cell lines , 2006 .

[59]  J. Schuhmacher,et al.  Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate , 2004, European Journal of Nuclear Medicine.

[60]  Charles R. Thomas,et al.  Radiation medicine innovations for the new millenium. , 2003, Journal of the National Medical Association.

[61]  M. Salvatore,et al.  Radiolabeling approaches for cholecystokinin B receptor imaging. , 2002, Biopolymers.

[62]  C. Grana,et al.  90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. , 2002, Biopolymers.

[63]  G R Marshall,et al.  Peptide interactions with G-protein coupled receptors. , 2001, Biopolymers.

[64]  D. Mierke,et al.  Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin A receptor. , 2001, Biochemistry.

[65]  M. Pellegrini,et al.  Structural characterization of peptide hormone/receptor interactions by NMR spectroscopy. , 1999, Biopolymers.

[66]  R. Ladner,et al.  Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  J R Gunn,et al.  Computational studies of protein folding. , 1996, Annual review of biophysics and biomolecular structure.

[68]  M. Schwartz,et al.  Integrins: emerging paradigms of signal transduction. , 1995, Annual review of cell and developmental biology.

[69]  R. S. Wu.  Novel bifunctional linkers for antibody chelation with radiometals. , 1990, Cancer treatment and research.

[70]  D Rodbard,et al.  DESIGN: computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. II. Simultaneous analysis of homologous and heterologous competition curves and analysis blocking and of "multiligand" dose-response surfaces. , 1990, Analytical biochemistry.

[71]  P J Munson,et al.  LIGAND: a computerized analysis of ligand binding data. , 1983, Methods in enzymology.

[72]  J. Brown,et al.  Monoclonal antibodies to tumor antigens. , 1980, Contemporary topics in immunobiology.